Compare Moderna, Inc. (MRNA) vs Palantir Technologies Inc (PLTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Palantir Technologies Inc — how do they compare? Moderna, Inc. trades at $204.19 (market cap $78.65B), while Palantir Technologies Inc trades at $199.36 (market cap $477.68B). The key difference: Palantir Technologies Inc is far larger — about 6.1× Moderna, Inc.'s market cap, and Palantir Technologies Inc is more actively traded (41,744,992 versus 37,373,437). Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Palantir Technologies Inc for 78 Days on average.
| MRNA | PLTR | |
|---|---|---|
Market Cap | $78.65B | $477.68B |
Volume | 37,373,437 | 41,744,992 |
Sector | Health | Technology |
52-Week High | $203.46 | $207.18 |
52-Week Low | $22.36 | $107.27 |
Typical Hold Time | 59 Days | 78 Days |
Enterprise Value | $74.80B | $468.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Palantir (PLTR) trades at $194.04, up 1.02% today, near its recent high and above the consensus price target of $191.69. The stock shows a bullish technical trend with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company reported robust revenue of $4.48 billion in 2025, with net income surging to $1.63 billion and a net margin of 36.3%, while recent quarters have consistently beaten EPS expectations.
Outlook remains positive driven by AI platform growth and expanding commercial customer base, but high valuation ratios (P/E of 169.9, P/S of 83.02) pose risks. Investor sentiment is buoyed by analyst buy ratings (53.84%) and partnerships like the recent Armada alliance, though competitive pressures and execution challenges are key watchpoints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →
